

# Wade J Sexton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2957989/publications.pdf>

Version: 2024-02-01

66  
papers

1,389  
citations

430442

18  
h-index

360668

35  
g-index

66  
all docs

66  
docs citations

66  
times ranked

1938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2004, 22, 439-445.	0.8	356
2	Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 339.e17-339.e23.	0.8	91
3	Bladder Cancer: A Review of Non-Muscle Invasive Disease. <i>Cancer Control</i> , 2010, 17, 256-268.	0.7	75
4	Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. <i>BJU International</i> , 2015, 116, 196-201.	1.3	62
5	Zonal NePhRO Scoring System: A Superior Renal Tumor Complexity Classification Model. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e13-e18.	0.9	47
6	Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. <i>Journal of Urology</i> , 2017, 198, 281-288.	0.2	47
7	Detection of Productively Rearranged TcR-Î± Vâ€¦ Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. <i>Cancer Informatics</i> , 2016, 15, CIN.S35784.	0.9	46
8	Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 82-88.	0.9	42
9	Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. <i>Journal of Urology</i> , 2017, 198, 1346-1352.	0.2	38
10	Using Percentage of Sarcomatoid Differentiation as a Prognostic Factor in Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 225-230.	0.9	35
11	Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. <i>Oncolmmunology</i> , 2018, 7, e1476816.	2.1	32
12	Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 47-52.	0.2	29
13	Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. <i>World Journal of Urology</i> , 2015, 33, 1585-1592.	1.2	27
14	Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. <i>Urology</i> , 2018, 117, 95-100.	0.5	26
15	Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. <i>BMC Anesthesiology</i> , 2018, 18, 157.	0.7	26
16	Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. <i>European Urology Oncology</i> , 2021, 4, 93-101.	2.6	25
17	Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 984.	2.3	24
18	Disparities in Interpretation of Primary Testicular Germ Cell Tumor Pathology. <i>American Journal of Clinical Pathology</i> , 2015, 144, 289-294.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. <i>World Journal of Urology</i> , 2016, 34, 1567-1573.	1.2	19
20	Salvage Surgical Resection for Isolated Locally Recurrent Inguinal Lymph Node Metastasis of Penile Cancer: International Study Collaboration. <i>Journal of Urology</i> , 2014, 192, 760-764.	0.2	18
21	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoablative Nephrectomy with Thrombectomy. <i>European Urology Focus</i> , 2020, 6, 104-111.	1.6	18
22	Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. <i>Urology</i> , 2017, 105, 108-112.	0.5	16
23	Influence of gene expression on survival of clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2020, 9, 8662-8675.	1.3	16
24	Perivascular epithelioid cell tumor (PEComa) of the urinary bladder associated with Xp11 translocation. <i>Annals of Clinical and Laboratory Science</i> , 2014, 44, 91-8.	0.2	16
25	Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center. <i>World Journal of Surgery</i> , 2018, 42, 2701-2707.	0.8	15
26	Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. <i>Urology</i> , 2015, 86, 321-326.	0.5	14
27	Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies. <i>Urologic Clinics of North America</i> , 2015, 42, 277-285.	0.8	14
28	Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. <i>World Journal of Urology</i> , 2017, 35, 657-663.	1.2	13
29	Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1003-e1013.	0.9	12
30	Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. <i>World Journal of Urology</i> , 2022, 40, 1505-1512.	1.2	12
31	Outcomes after inferior vena cava thrombectomy and reconstruction for advanced renal cell carcinoma with tumor thrombus. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2014, 2, 368-376.	0.9	11
32	Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e23-112.e29.	0.8	11
33	Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. <i>Urology</i> , 2017, 103, 142-148.	0.5	11
34	Valrubicin in refractory non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1379-1387.	1.1	10
35	Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e1-14.e5.	0.8	10
36	Impact of CoVID-19 on resident and fellow education: Current guidance and future opportunities for urologic oncology training programs. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 357-364.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Is surgeon intuition equivalent to models of operative complexity in determining the surgical approach for nephron sparing surgery?. Indian Journal of Urology, 2016, 32, 124.	0.2	10
38	Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 911-919.	0.7	9
39	Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. Journal of Urology, 2015, 194, 1220-1225.	0.2	9
40	Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Translational Andrology and Urology, 2020, 9, S91-S103.	0.6	9
41	Robotic-Assisted Renal Surgery. Cancer Control, 2015, 22, 291-300.	0.7	7
42	Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 7.e9-7.e18.	0.8	6
43	The human, F-actin-based cytoskeleton as a mutagen sensor. Cancer Cell International, 2017, 17, 121.	1.8	5
44	Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients's™ Voice or a Missed Opportunity. Clinical Genitourinary Cancer, 2022, 20, e158-e165.	0.9	5
45	Identifying unrecognized collecting system entry and the integrity of repair during open partial nephrectomy: comparison of two techniques. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 637-643.	0.7	4
46	Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs. Pathology and Oncology Research, 2016, 22, 115-120.	0.9	4
47	Robotic-assisted partial cystectomy with enBloc excision of the urachus and the umbilicus for urachal adenocarcinoma. Journal of Robotic Surgery, 2010, 3, 235-238.	1.0	3
48	Are there differences in zonal distribution and tumor volume of prostate cancer in patients with a positive family history?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 571-582.	0.7	3
49	Trends in Insurance Status during Initial Presentation of Testicular Carcinoma: Examining Health Outcomes and Implications of Health Reform for Young Adults in the United States. Urology Practice, 2019, 6, 18-23.	0.2	3
50	Outcomes in Renal Cell Carcinoma With IVC Thrombectomy: A Multiteam Analysis Between an NCI-Designated Cancer Center and a Quaternary Care Teaching Hospital. American Surgeon, 2020, 86, 1005-1009.	0.4	3
51	Nephrectomy and inferior vena cava thrombectomy for renal cell carcinoma among patients with impaired renal function: defining predictors of outcomes. ANZ Journal of Surgery, 2016, 86, 44-48.	0.3	2
52	Sociodemographic and Provider Based Disparities in the Management of Stage I Testicular Cancer. Urology Practice, 2017, 4, 36-42.	0.2	2
53	Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Annals of Surgical Oncology, 2021, 28, 3648-3655.	0.7	2
54	Bilateral testicular adrenal rest tumors in a patient with nonclassical congenital adrenal hyperplasia. IJU Case Reports, 2021, 4, 243-246.	0.1	2

#	ARTICLE	IF	CITATIONS
55	Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. <i>Urology Annals</i> , 2016, 8, 151.	0.3	2
56	Telomere length in peripheral blood leukocytes and risk of renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S397-S403.	0.4	2
57	Management of Urethral Recurrences. <i>Urologic Clinics of North America</i> , 2016, 43, 515-521.	0.8	1
58	Optimal Management of High-risk Stage I Nonseminoma Germ Cell Tumor: Active Intervention is the Preferred Option. <i>European Urology Focus</i> , 2019, 5, 704-705.	1.6	1
59	Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.. <i>Journal of Clinical Oncology</i> , 2020, 38, 646-646.	0.8	1
60	Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-GuÃ©rin. <i>Journal of Urology</i> , 2022, 208, 526-527.	0.2	1
61	Initial experience with robot-assisted retroperitoneal partial nephrectomy for suspected renal cell carcinoma. <i>Journal of Robotic Surgery</i> , 2014, 8, 305-311.	1.0	0
62	Author Reply. <i>Urology</i> , 2017, 103, 148.	0.5	0
63	Focused issue on testicular cancerâ€™forward. <i>Translational Andrology and Urology</i> , 2020, 9, S1-S2.	0.6	0
64	Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	0.8	0
65	Adenocarcinoma of the Urinary Bladder. , 2012, , 195-213.		0
66	Association of positive Ki-67 and PD-L1 expressions in post neoadjuvant chemotherapy (NAC) radical cystectomy samples with lack of tumor downstaging (TD) and shorter overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 554-554.	0.8	0